# A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition

> **NCT05874180** · PHASE1 · COMPLETED · sponsor: **Dong Wha Pharmaceutical Co. Ltd.** · enrollment: 31 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** DW6013

## Key facts

- **NCT ID:** NCT05874180
- **Lead sponsor:** Dong Wha Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-09
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-02-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05874180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05874180, "A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05874180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*